You searched for "PSA"
Demanding cases or nightmares in uro-oncology? Sep/Oct 2022
Treatment of prostate cancer in renal transplant recipients is challenging due to a lack of knowledge of the natural history of cancer in these patients, the anatomical position of the graft in the iliac fossa and its proximity to the...Improving on the Rotterdam Prostate Cancer Risk Calculator
Following the PROMIS trial [1], many cancer centres in the UK are now offering pre-biopsy multiparametric MRI (mpMRI) for men suitable for radical treatment. The European Association of Urology for Prostate Cancer (PCa) guidelines recommend individual risk stratification before the...
ASAP: is a repeat biopsy necessary?
This study examined the validity of current US and European guidelines on the management of patients diagnosed with atypical small acinar proliferation (ASAP). Current guidance states that these patients should undergo repeat biopsy within three to six months due to...
Activity of enzalutamide in men with mCRPC is affected by prior treatment with abiraterone and / or docetaxel
This study reported on the real-world clinical outcomes of patients at seven academic institutions who were treated with enzalutamide, with the primary objective being to assess the effect of prior therapies (namely abireterone and docetaxel). Three hundred and ten patients...
Performance status may alter outcomes in those treated with abiraterone
The drug therapies available for those with metastatic castrate-resistant prostate cancer have increased over the past few years. Abiraterone, a CYP17 inhibitor, has been proven effective in phase three trials, however those with poor performance status were largely under-represented in...Prostate cancer series: diagnostics 1
- Click here for Part 2 - A 58-year-old male is referred to your rapid access prostate clinic with a prostate specific antigen (PSA) of 6.0ng/ml. He has no lower urinary tract symptoms (LUTS), past medical history (PMH), or family...
Prostate cancer screening
This editorial is from the University of Minnesota in the USA. The present evidence suggests that prostate specific antigen (PSA) testing provides a small reduction in prostate cancer (CaP) mortality and no reduction in all-causes mortality. The downside is of...
Association of prostate size with capsule thickness and glandular epithelial cell density
Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are two significant urologic diseases affecting ageing men. BPH is histologically evident in over half of men above 50, while PCa is a highly lethal cancer prevalent in men in the United...APCCC (Advanced Prostate Cancer Consensus Conference) Diagnostics 2025
The diagnostic abilities for assessing prostate cancer patients have significantly evolved in the last years. Ranging from advanced imaging modalities for detection, new innovative liquid and tissue based biomarkers as well as the recent introduction of PSMA PET imaging have significantly advanced the field, challenging some of the old grounds of truth.Prostate cancer management 1 – non-metastatic disease
You are referred a 68-year-old gentleman to the rapid access prostate clinic with a serum prostate specific antigen (PSA) of 12ug/L. He is otherwise fit and well with mild voiding lower urinary tract symptoms (LUTS). He undergoes a multi parametric...‘Man van’ launched to speed up cancer diagnosis and improve healthcare access
The ‘Man Van’, an innovative new outreach programme, was launched in March this year to provide free health checks for men and boost early diagnosis of prostate and other urological cancers. The mobile health clinic will visit workplaces and churches...
